Glyprotect

Glyprotect is a German biotechnology company focused on developing innovative therapies to protect and restore the mucosal barrier in the gastrointestinal tract and other organs. The company's core technology involves small molecules and peptides designed to stabilize the mucus layer, specifically targeting Mucin-2 to prevent degradation by bacterial enzymes and inflammatory processes. By shielding the mucosal lining, Glyprotect aims to treat chronic inflammatory conditions such as ulcerative colitis and Crohn's disease, as well as radiation-induced tissue damage. The company is a spin-off from the University of Bonn, leveraging deep expertise in glycobiology and mucosal immunology to address significant unmet needs in gastroenterology and beyond.